Have a feature idea you'd love to see implemented?
Let us know!
OCUL Ocular Therapeutix Inc
Price (delayed)
$8.52
Market cap
$1.34B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$985.78M
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation
Highlights
The debt has contracted by 10% YoY
The revenue has grown by 6% YoY
The net income has dropped by 160% year-on-year and by 26% since the previous quarter
The company's EPS has shrunk by 53% YoY and by 19% QoQ
Key stats
What are the main financial stats of OCUL
Market
Valuations
Earnings
Shares outstanding
157.22M
Market cap
$1.34B
Enterprise value
$985.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.77
Price to sales (P/S)
23.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.04
Revenue
$61.44M
EBIT
-$159.72M
EBITDA
-$155.92M
Free cash flow
-$119.25M
Per share
Balance sheet
Liquidity
EPS
-$1.32
Free cash flow per share
-$0.71
Book value per share
$2.26
Revenue per share
$0.37
TBVPS
$2.94
Total assets
$490.37M
Total liabilities
$138.35M
Debt
$75.12M
Equity
$352.02M
Working capital
$436.65M
Debt to equity
0.21
Current ratio
13.01
Quick ratio
12.63
Net debt/EBITDA
2.27
Margins
Efficiency
Dividend
EBITDA margin
-253.8%
Gross margin
90.6%
Net margin
-283.7%
Operating margin
-229.9%
Return on assets
-38.8%
Return on equity
-56.7%
Return on invested capital
-156.4%
Return on capital employed
-35.2%
Return on sales
-260%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCUL stock price
How has the Ocular Therapeutix stock price performed over time
Intraday
-2.96%
1 week
-14.11%
1 month
-25.07%
1 year
289.04%
YTD
91.03%
QTD
-2.07%
Financial performance
How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$61.44M
Gross profit
$55.66M
Operating income
-$141.26M
Net income
-$174.34M
Gross margin
90.6%
Net margin
-283.7%
The net income has dropped by 160% year-on-year and by 26% since the previous quarter
The net margin has plunged by 144% YoY and by 25% from the previous quarter
The operating income has plunged by 73% YoY and by 23% from the previous quarter
Ocular Therapeutix's operating margin has plunged by 62% YoY and by 23% from the previous quarter
Growth
What is Ocular Therapeutix's growth rate over time
Valuation
What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
3.77
P/S
23.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.04
The company's EPS has shrunk by 53% YoY and by 19% QoQ
OCUL's price to book (P/B) is 83% less than its 5-year quarterly average of 22.7 but 8% more than its last 4 quarters average of 3.5
The equity has declined by 7% since the previous quarter
The stock's P/S is 35% above its last 4 quarters average of 17.1 but 6% below its 5-year quarterly average of 24.7
The revenue has grown by 6% YoY
Efficiency
How efficient is Ocular Therapeutix business performance
The company's return on sales has shrunk by 159% YoY and by 29% QoQ
OCUL's return on invested capital has dropped by 133% year-on-year and by 29% since the previous quarter
Ocular Therapeutix's return on equity has surged by 88% YoY and by 9% QoQ
The return on assets has grown by 19% year-on-year but it has declined by 3.2% since the previous quarter
Dividends
What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCUL.
Financial health
How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's quick ratio has decreased by 23% QoQ
The current ratio has contracted by 22% from the previous quarter
The debt is 79% less than the equity
The company's debt to equity has shrunk by 98% YoY but it rose by 5% QoQ
The debt has contracted by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.